Aclarion (ACON) Projected to Post Quarterly Earnings on Thursday

Aclarion (NASDAQ:ACON) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($2.64) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 21, 2025 at 9:30 AM ET.

Aclarion (NASDAQ:ACON) last released its quarterly earnings data on Thursday, August 14th. The company reported ($2.75) EPS for the quarter, missing the consensus estimate of ($2.26) by ($0.49). Aclarion had a negative return on equity of 83.63% and a negative net margin of 11,238.59%.The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, analysts expect Aclarion to post $-263 EPS for the current fiscal year and $-217 EPS for the next fiscal year.

Aclarion Stock Performance

NASDAQ ACON opened at $7.10 on Wednesday. The company has a market cap of $4.12 million, a PE ratio of -0.01 and a beta of 1.42. Aclarion has a 52-week low of $6.20 and a 52-week high of $3,499.51. The firm’s 50 day moving average price is $7.84 and its 200-day moving average price is $7.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Aclarion has a consensus rating of “Reduce” and a consensus target price of $11,758.50.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.